Pyrimethamine is listed as one of the top drugs on the World Health Organization’s essential drugs list. Pyrimethamine selectively inhibits the Plasmodium form of dihydrofolate reductase and reduces the production of folic acid, which is necessary for the synthesis of Plasmodium’s nucleic acid.
As of 2022, the Global Pyrimethamine Market is estimated to be valued at U.S.$ 1,106.8 Million and expected to increase to U.S$ 1,655.1 Million by 2030, witnessing a CAGR of 5.2% during the years 92022-2030)
Major Players in the Pyrimethamine Industry:
1) GlaxoSmithKline GSK plc.
GSK Plc. Is a British Multinational pharmaceutical and biotechnology company founded in the year 2000. The headquarters are located in London, England, UK. GlaxoSmithKline is the tenth largest pharmaceutical company and has ranked 294th on the 2002 Fortune Globes 500. The company was founded by Joseph Nathan. The company manufacture products for major diseases like asthma, cancer, infections and mental health.
In April 2022, the company announced its plans of acquiring Sierra Oncology Inc. for U.S$ 1.9 Billion. In May 2022, GSK announced it would acquire Affinivax and its phase II 24- Valent pneumococcal vaccine candidate for up to $3.3 Billion.
2) Abcam Plc.
Abcam is a producer, distributor and seller of protein research tools. The company identifies, develops, and provides high-quality biological reagents and tools that are essential and required in a wide range of fields and applicants including drug discovery, diagnostics and basic research. The company was founded in the year 1998, and the headquarters are located in Cambridge, UK. The company was founded by Jonathan Miller.
